Limited preclinical evidence has been generated in BC models harboring RET rearrangements with the available evidence indicating that cabozantinib reduces the proliferative potential of breast cancer cells displaying the NCOA4-RET fusion (52). This evidence concerns the gene RET and breast cancer.